These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 6345112)

  • 1. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.
    Chan RP; Pope DJ; Gilbert AP; Sacra PJ; Baron JH; Lennard-Jones JE
    Dig Dis Sci; 1983 Jul; 28(7):609-15. PubMed ID: 6345112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K; Williams JG
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Balsalazide.
    Prakash A; Spencer CM
    Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV; Kane SV; Bjorkman D
    Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
    Edmond LM; Hopkins MJ; Magee EA; Cummings JH
    Inflamm Bowel Dis; 2003 Jan; 9(1):10-7. PubMed ID: 12656132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
    Kane SV; Bjorkman DJ
    Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
    Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
    Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
    Giaffer MH; Holdsworth CD; Lennard-Jones JE; Rodrigues CA; McIntyre PB; Manjunatha S; Baron JH; Barrison IG; Polson RJ; Hoare AM
    Aliment Pharmacol Ther; 1992 Aug; 6(4):479-85. PubMed ID: 1358234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ; Hanauer SB; Buch A
    Aliment Pharmacol Ther; 2004 May; 19(10):1089-98. PubMed ID: 15142198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
    Kles KA; Vavricka SR; Turner JR; Musch MW; Hanauer SB; Chang EB
    Inflamm Bowel Dis; 2005 Mar; 11(3):253-7. PubMed ID: 15735431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal with balsalazide of infertility caused by sulphsalazine.
    McIntyre PB; Lennard-Jones JE
    Br Med J (Clin Res Ed); 1984 Jun; 288(6431):1652-3. PubMed ID: 6144351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.